Page 1923 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

1350 Index

Pattern recognition receptors (PRRs), 552 aspiration, 1052 Physician-assisted death (PAD), 128
Pediatric cardiac arrest, 167 atelectasis, 1049–1051, 1049f, 1052ft Physician extenders, nonphysician providers
Pediatric Risk of Mortality (PRISM) predicting and preventing perioperative as, 17–19, 17t, 18t
score, 85 lung dysfunction, 1052 Physician orders for life-sustaining treatment
Pelvic ring injuries, 1168–1172, 1168t treatment principles for perioperative (POLST), 127
anatomy, 1168–1169, 1169f respiratory failure, 1052–1053 Physiological regulation of blood glucose,
clinical assessment, 1170, 1171f Perioperative ß-blockade, 1056 142, 142f
complications, 1172, 1172f Peripheral nerve injuries, 1178 Physiologic response to anemia, 842
management of, 1170–1172, 1171f Perirectal infections, 617 PiCCO™ system, 247, 248
mechanism and injury classification, Peritonitis Picornaviridae, 672–673
1169–1170, 1180f primary, 1079–1080 Picture Archiving and Communication
https://kat.cr/user/tahir99/
radiographic assessment, 1170, 1171f secondary bacterial, 1080–1082, System (PACS), 55
Pemphigus vulgaris, 1290–1292, 1291f 1081t, 1082f Pinch-off phenomenon, 225, 225f
Penicillins, 545, 549t Peritonsillar abscesses, 407, 680f, 683–684 Pinch purpura, 1294
Pentamidine, 632 Persistent fever, 557–562 Plague, 719, 745–747
Pentax AWS™, 390 differential diagnosis of fever in ICU, Plasmapheresis/therapeutic plasma exchange
Pentobarbital, 1135 558, 558t in critically ill patient, 1253
Pentobarbital coma, 810 epidemiology and impact of, 557–558 Plasma viral load, 626
Peptic ulcers, endoscopic therapy for, selected infectious causes of, 558–559 Platelet activating factor (PAF), 565
1014–1017, 1015f, 1016f selected noninfectious causes of Platelet-derived growth factor
Percutaneous abscess drainage, hyperthermia and, 559–561 (PDGF), 566
209–211, 210f temperature regulation and measurement, Platelet disorders, 332, 849–853,
Percutaneous cholecystostomy, 212–214, 557, 557f 850t, 851t
213f, 214f treatment of, 561 Platelet glycoprotein receptors,
Percutaneous dilational tracheostomy, 399 Persistent vegetative state, 829–830 disorders of, 846
technique of, 399–400 prognosis and, 838–839 Platelet physiology and function, 846
Percutaneous nephrostomy, 211–212, Pharmacists, intensive-care unit staffing Platelet transfusion, 856
211f, 212f by, 21–22 Pleural effusion, 507, 507f
Percutaneous tracheostomy, 394–395 Pharmacodynamic modeling, 1226–1227 Pleural pressure, dynamic predictors relying
Performance, 33 Pharmacodynamics in critically ill patients, on perturbing, 264–265
measuring, 33 544–545, 544f Pneumococcal meningitis, 652–653
statistical control charts for Pharmacogenetics, 1234t, 1235, 1235t, 1236 Pneumocystis jiroveci pneumonia,
monitoring, 9t, 10 Pharmacokinetics in critically ill patients, 629–635
Pericardial diseases, 336–343 544–545, 544f clinical and radiologic features, 630, 635f
acute pericarditis, 336–338 Pharmacologic agents, 107 diagnosis of, 630–631
diagnosis of, 336–337, 337ft Pharmacologic anticoagulants, 854–855 management of, 632, 632–634t
management of, 337–338 Pharmacologic control of blood pressure, prognosis, 634–635
cardiac tamponade, 338–340 363–365 Pneumonia, 559, 576–587
diagnosis of, 338–339, 338f acute management of, 363–364, 363t bronchiolitis obliterans organizing, 888
invasive hemodynamics, 339, 339f chronic management of, 364 community-acquired
pathophysiology, 338 definitive management of, 364–365, 365f complications, 583–584
pericardiocentesis, 339–340, 339f Pharmacologic therapy of cardiac arrest, criteria for ICU, 582, 582t
constrictive pericarditis, 340–342 173, 173t diagnosis of, 581–582, 581t
cardiac catheterization, 342 Pharmacology. See Critical care pharmacology epidemiology, 580
clinical evaluation, 341 Phase II enzyme polymorphism, 1236 etiologic spectrum, 580–581, 581t
echocardiography, 341–342, 342f Phenobarbital for status epilepticus, 784–785 prevention of, 584
pathophysiology, 340, 341f Pheochromocytoma, 260, 1076 treatment of, 583, 583t
treatment of, 342 Phosphorus, 962–965 community-acquired pneumonia,
Pericardial effusions, 880 hyperphosphatemia, 964–965, 965t 580–584
Pericardial friction rub, 337 hypophosphatemia, 962–964, 963t, 964t as complication of drowning, 1325
Pericardial tamponade, 198, 200f metabolism, 962 general treatment strategies
Pericardiocentesis, 305, 339–340, renal handling of, 962 antibiotic, 580
339f Physical therapy, 162–166 septic shock, 580
Pericardium, 336 active range of motion, 163–164 ventilatory support, 580
Pericranial infections, 685–686, 685t assistive technologies, 165 health-care associated, 584–585
Periengraftment respiratory distress bed rest and immobility, 162 definition, 584
syndrome, 887 early mobilization, 164–165 epidemiology of, 584
Perinephric abscess, 700 inactivity and muscle weakness, 162–163 etiologic spectrum and recommended
Perioperative lung dysfunction, inactivity and other organ system antibiotic therapy, 584–585
predicting, 1052 injury, 163 hospital-acquired, 585–587
Perioperative management, sickle cell disease mobilization of critically ill patient, 163 altered pathogenesis and
and, 912 passive range of motion, 163 pathophysiology, 585
Perioperative respiratory failure, practical implementation of an exercise and antibiotic therapy, 586–587, 586t
1048–1053 mobilization program in acute care diagnosis of, 585, 585t
pulmonary edema, 1048–1049 intensive-care unit, 165–166 etiologic spectrum, 585–586
alveolar hypoventilation, 1051–1052 survivorship, 162 prevention, 587, 587t

Index.indd 1350 23-01-2015 15:33:53